\
&
Contact us
\
&
Contact us
This was 1 year ago
LocationHybrid - Brussels and online
This information and brokerage session will inform participants about the Horizon Europe 2024 calls on world leading data and computing technologies and digital and emerging technologies for competitiveness and that are aligned with the Green Deal objectives.
Introduction to Horizon Europe Calls will be given by Rolf Riemenschneider - Head of Sector IoT and Luis C. Busquets Pérez - Programme Officer, DG Connect, European Commission.
The main motivation is to brainstorm ideas and proposals regarding the open Calls of Horizon Europe, to network with potential project partners, as well as to build successful partnerships with academics, researchers, industrial stakeholders, and SMEs.
Closing date for pitch registration is 20 November 2023. You may also upload your profile.
If you wish to participate in person, make sure you register as soon as possible, as venue capacity is limited.
For more information on the event please visit the event website. Registration (by 1 December at the latest) is possible via the registration link on this website.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The Horizon2020 project BEAT-AF brings together 9 European renowned clinical centres in France, Belgium, Czechia, Germany and Austria. Together, the consortium strives to revolutionize Atrial Fibrillation (AF) treatment through catheter ablation and contribute to decrease the huge burden of AF in Europe. The BEAT-AF project kicked off in 2021 and will run until 2026. The department of electrophysiology of the AZ Sint-Jan Hospital in Bruges is partner in the project and has so far contributed to the pre-clinical development, the first in man studies and first registries of the revolutionary AF treatment put forward by the consortium. The first pilot studies show that the treatment is safe, effective and efficient.
